Yes!  I want to receive ReSPECT-GBM Clinical Trial updates for recurrent glioblastoma!

Not ready to sign up yet?

Explore the ReSPECT-GBM website here.

Yes! I want to receive ReSPECT-GBM Clinical Trial updates for recurrent glioblastoma!

Not ready to sign up?

Explore the ReSPECT-GBM website here.

The purpose of the ReSPECT-GBM clinical trial is to assess the safety, tolerability, and distribution of an innovative, targeted radiotherapeutic, 186RNL (Rhenium-186 NanoLiposome), in adults with recurrent glioblastoma after standard surgical, radiation, and/or chemotherapy treatment.  The ReSPECT-GBM clinical trial is supported by the U.S. National Institutes of Health.

Subscribe to Email Alerts

  • Principal Investigators

  • Trial Locations

  • Patient Enrollment

  • Timeline

  • News and Presentations

  • Publications

To opt-in, please complete the form above.